Press releases

Data was presented at SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago

Results from TAXUS IV and V randomized clinical trials favor DES compared to bare-metal stents

At two years, Company's TAXUS® and PROMUS™ Stents demonstrate positive and similar outcomes

Sale is the latest example of Company's commitment to realigning its cost structure; overall goal is to strengthen Boston Scientific for the future

Two-year outcomes confirm the favorable results seen in previous clinical trials

One-year pooled ARRIVE data showed similarly low rates of stent-related cardiac death, myocardial infarction, stent thrombosis, and major cardiac events across the two patient subsets

Presentations to include clinical data for the TAXUS® paclitaxel-eluting coronary stent in a variety of high-risk patient populations

A live webcast and replay of the March 18 session will be available. Learn how to tune in

ACUITY® Spiral lead offers flexibility for placement in small, medium and large veins

Forty implants of COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN™ implantable cardioverter defibrillator (ICD) performed in 14 hospitals in six countries

Jay J. Schnitzer, M.D., Ph.D. to join Company's Clinical Sciences organization effective March 24

Approvals include CONFIENT™ ICD, LIVIAN™ CRT-D and upgraded LATITUDE® Patient Management System

Completes Company's previously announced plans to divest five non-strategic businesses

Company plans to seek to overturn patent infringement lawsuit verdict in post-trial motions

PROENCY will provide real-world clinical data on the PROMUS™ Stent

"The turn that began last quarter continued this quarter, with strong adjusted earnings and record sales," said Jim Tobin, President and Chief Executive Officer

'Close the Gap' brings together advocates from cardiologists to coaches

A live webcast and replay of the February 6 session will be available.

NEJM article is entitled "A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications"

A live webcast and replay of the February 5 conference call will be available

CE Mark approvals are for COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN™ implantable cardioverter defibrillator (ICD)

Ruling finds the NIR® stent, formerly sold by Company, infringed one claim of a patent owned by Johnson & Johnson

Divestitures are part of ongoing efforts to simplify operating model and restore profitable growth

Company retains ownership of Pain Management business

A live webcast and replay of the January 9 session will be available